Technologies for Genomic Medicines
Sangamo is developing new genomic medicines which may address the underlying mistakes in DNA that lead to some genetic diseases.
delivery and manufacturing
We use both adeno-associated virus (AAV) and mRNA to deliver our therapeutics and continue to develop and refine these platforms as well as our manufacturing processes for therapeutic cell production. Using our molecular biology and AAV expertise, we are also developing gene therapy approaches for key indications.
NEXT GENERATION ZFNS
Our scientists are continuously aiming to improve our ZFN technology around the key genome editing parameters of precision, efficiency, and specificity. Learnings from the application of zinc finger technology in the clinic informs our research priorities with regards to ZFN improvements.